[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Views 1,176
Citations 0
January 6, 2015

Cost Correction

JAMA. 2015;313(1):95. doi:10.1001/jama.2014.16454

In the article from The Medical Letter on Drugs and Therapeutics entitled “Drugs for MRSA Skin and Soft-Tissue Infections” published in the October 15, 2014, issue of JAMA (2014;312[15]:1583-1584. doi:10.1001/jama.2014.13385), the cost of tedizolid in Table 1 was reported as $2950 for 10 days’ treatment. Cubist’s tedizolid (Sivextro) received FDA approval for 6 days’ treatment of acute bacterial skin and skin structure infection, which would cost $1770. This article was corrected online.